Study Group: Neurologists (EU)(?)
Council Members in this Study Group: 544
Request a survey with this Study Group
Related Study Groups
| Study Group Name | Members |
|---|---|
| Neurologists | 1823 |
| Neurologists (UK) | 145 |
| Physicians who Treat Multiple Sclerosis (EU) | 115 |
| Multiple Sclerosis Neurologists (EU) | 102 |
| Physicians (Germany) | 1146 |
| Neurologists who Treat Alzheimer's Disease (EU) | 76 |
| Clinical Neurophysiologists (EU) | 71 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
I am not sure that 4-aminopyridine, a long known drug, will efectively improve walking. As important as the walking ability are other clinical features of MS, e.g. ataxia, dementia or bladder dysfunction. This should also be tested.
There is not much information of the drug ALS-02 in the paper. The term neuroprotection is defined not very well and describes a great number of different molecular mechanisms. The low number of patients will not allow implications for clinical efficacy.
The most recently reported data on Betaseron highlight the usefulness of early treatment of multiple sclerosis (MS) patients. These results allow to widen significantly the number of potential users of Betaseron. They are consistent with the results previously obtained with Avonex, one of...
To evaluate further the role of surgery vs. medical treatment.
There will be increased public demand for the new devices which are perceived as superior to the traditional way of operating cervical discs.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Professor
- Director
- Physician - Department Chair
- Research Scientist
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms